{
    "body": "Which signaling pathway does sonidegib inhibit?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/24598114", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25981810", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24523439", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24613036", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25646180", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24817600", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24928708", 
        "http://www.ncbi.nlm.nih.gov/pubmed/25473003"
    ], 
    "ideal_answer": [
        "Sonidegib is a Hedghog signalling pathway inhibitor."
    ], 
    "exact_answer": [
        "Hedghog signalling pathway"
    ], 
    "type": "factoid", 
    "id": "56d0451c3975bb303a00000e", 
    "snippets": [
        {
            "offsetInBeginSection": 942, 
            "offsetInEndSection": 1066, 
            "text": "The association between Hh activation status and tumor response to the Hh pathway inhibitor sonidegib (LDE225) was analyzed.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25473003", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 9, 
            "offsetInEndSection": 129, 
            "text": "Distinct molecular subgroups of medulloblastoma, including hedgehog (Hh) pathway-activated disease, have been reported. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25473003", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 166, 
            "offsetInEndSection": 296, 
            "text": "We assessed the antitumour activity of sonidegib, a Hedgehog signalling inhibitor, in patients with advanced basal cell carcinoma.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25981810", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 677, 
            "offsetInEndSection": 989, 
            "text": "Among such pathways, RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, EGFR, and Notch are of particular interest because agents that selectively inhibit these pathways are available and can be readily combined with agents such as vismodegib, sonidegib (LDE225), and BMS-833923, which target smoothened-a key Hh pathway regulator.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24613036", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 341, 
            "text": "This phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the novel smoothened inhibitor sonidegib (LDE225), a potent inhibitor of hedgehog signaling, in patients with advanced solid tumors.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24523439", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 150, 
            "text": "The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24817600", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1598, 
            "offsetInEndSection": 1830, 
            "text": "Future studies, including one combining the Hh pathway inhibitor sonidegib and the JAK2 inhibitor ruxolitinib, are underway in patients with MF and will inform whether this combination approach can lead to true disease modification.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24598114", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 282, 
            "offsetInEndSection": 412, 
            "text": "We assessed the antitumour activity of sonidegib, a Hedgehog signalling inhibitor, in patients with advanced basal cell carcinoma.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25981810", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 166, 
            "offsetInEndSection": 378, 
            "text": "We assessed the antitumour activity of sonidegib, a Hedgehog signalling inhibitor, in patients with advanced basal cell carcinoma.METHODS: BOLT is an ongoing multicentre, randomised, double-blind, phase 2 trial. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25981810", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 646, 
            "text": "PURPOSE: This phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the novel smoothened inhibitor sonidegib (LDE225), a potent inhibitor of hedgehog signaling, in patients with advanced solid tumors. EXPERIMENTAL DESIGN: Oral sonidegib was administered to 103 patients with advanced solid tumors, including medulloblastoma and basal cell carcinoma (BCC), at doses ranging from 100 to 3,000 mg daily and 250 to 750 mg twice daily, continuously, with a single-dose pharmacokinetics run-in period. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24523439", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 160, 
            "text": "PURPOSE: The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24817600", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 88, 
            "offsetInEndSection": 520, 
            "text": "Hedgehog pathway signalling is aberrantly activated in around 95% of tumours. We assessed the antitumour activity of sonidegib, a Hedgehog signalling inhibitor, in patients with advanced basal cell carcinoma.METHODS: BOLT is an ongoing multicentre, randomised, double-blind, phase 2 trial. Eligible patients had locally advanced basal cell carcinoma not amenable to curative surgery or radiation or metastatic basal cell carcinoma. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25981810", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 278, 
            "text": "PURPOSE: The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects. METHODS: Six subjects received a single oral dose of 800 mg \u00b9\u2074C-sonidegib (74 kBq, 2.0 \u00b5Ci) under fasting conditions. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24817600", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 261, 
            "text": " The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects.  Six subjects received a single oral dose of 800 mg \u00b9\u2074C-sonidegib (74 kBq, 2.0 \u00b5Ci) under fasting conditions.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24817600", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1376, 
            "offsetInEndSection": 1611, 
            "text": "Future studies, including one combining the Hh pathway inhibitor sonidegib and the JAK2 inhibitor ruxolitinib, are underway in patients with MF and will inform whether this combination approach can lead to true disease modification.  .", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24598114", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 915, 
            "offsetInEndSection": 1039, 
            "text": "The association between Hh activation status and tumor response to the Hh pathway inhibitor sonidegib (LDE225) was analyzed.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25473003", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 617, 
            "text": " This phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the novel smoothened inhibitor sonidegib (LDE225), a potent inhibitor of hedgehog signaling, in patients with advanced solid tumors.  Oral sonidegib was administered to 103 patients with advanced solid tumors, including medulloblastoma and basal cell carcinoma (BCC), at doses ranging from 100 to 3,000 mg daily and 250 to 750 mg twice daily, continuously, with a single-dose pharmacokinetics run-in period.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24523439", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1203, 
            "offsetInEndSection": 1608, 
            "text": "Preliminary clinical data also suggest that inhibition of the Hh pathway, alone or in combination with JAK2 inhibition, may enable disease modification in patients with MF. Future studies, including one combining the Hh pathway inhibitor sonidegib and the JAK2 inhibitor ruxolitinib, are underway in patients with MF and will inform whether this combination approach can lead to true disease modification.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24598114", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 229, 
            "text": "The absorption, distribution, metabolism, and excretion of the hedgehog pathway inhibitor sonidegib (LDE225) were determined in healthy male subjects.  Six subjects received a single oral dose of 800 mg \u00b9\u2074C-sonidegib (74 kBq, 2.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24817600", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1392, 
            "offsetInEndSection": 1486, 
            "text": "including one combining the Hh pathway inhibitor sonidegib and the JAK2 inhibitor ruxolitinib,", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24598114", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 617, 
            "text": "This phase I trial was undertaken to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of the novel smoothened inhibitor sonidegib (LDE225), a potent inhibitor of hedgehog signaling, in patients with advanced solid tumors.  Oral sonidegib was administered to 103 patients with advanced solid tumors, including medulloblastoma and basal cell carcinoma (BCC), at doses ranging from 100 to 3,000 mg daily and 250 to 750 mg twice daily, continuously, with a single-dose pharmacokinetics run-in period.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24523439", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 77, 
            "offsetInEndSection": 285, 
            "text": "Hedgehog pathway signalling is aberrantly activated in around 95% of tumours. We assessed the antitumour activity of sonidegib, a Hedgehog signalling inhibitor, in patients with advanced basal cell carcinoma.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/25981810", 
            "endSection": "abstract"
        }
    ]
}